Universität zu Köln

Ernst, J. B., Prokop, S., Fuchs, U., Dreier, J., Kuhn, J., Knabbe, C., Berthold, H. K., Pilz, S., Gouni-Berthold, I., Gummert, J. F., Boergermann, J. and Zittermann, A. (2017). Randomized supplementation of 4000 IU vitamin D-3 daily vs placebo on the prevalence of anemia in advanced heart failure: the EVITA trial. Nutr. J., 16. LONDON: BIOMED CENTRAL LTD. ISSN 1475-2891

Full text not available from this repository.

Abstract

Background: Low 25-hydroxyvitamin D (25OHD) levels (<75 nmol/l) are inversely associated with anemia prevalence. Since anemia and low 25OHD levels are common in patients with heart failure (HF), we aimed to investigate whether vitamin D supplementation can reduce anemia prevalence in advanced HF. Methods: EVITA (Effect of Vitamin D on Mortality in Heart Failure) is a randomized, placebo-controlled clinical trial in patients with initial 25OHD levels <75 nmol/l. Participants received either 4000 IU vitamin D-3 daily or a matching placebo for 36 months. A total of 172 patients (vitamin D group: n = 85; placebo group: n = 87) were investigated in this pre-specified secondary data analysis. Hemoglobin (Hb) and other hematological parameters were measured at baseline and study termination. Assessment of between-group differences in anemia prevalence and Hb concentrations was performed at study termination, while adjusting for baseline differences. Results: In the vitamin D and placebo group, baseline proportions of patients with anemia (Hb < 12.0 g/dL in females and < 13.0 g/dL in males) were 17.2% and 10.6%, respectively (P = 0.19). At study termination, the proportion of patients with anemia in the vitamin D and placebo groups was 32.2% and 31.8%, respectively (P > 0.99). There was no between-group difference in change in the Hb concentrations (-0.04 g/dL [95% CI:-0.53 to 0.45 g/dL]; P = 0.87). Results regarding anemia risk and Hb concentrations were similar in the subgroup of patients with chronic kidney disease (vitamin D group: n = 26; placebo group: n = 23). Moreover, results did not differ substantially when data analysis was restricted to patients with deficient baseline 25OHD levels. Conclusions: A daily vitamin D supplement of 4000 IU did not reduce anemia prevalence in patients with advanced HF. Data challenge the clinical relevance of vitamin D supplementation to increase Hb levels.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ernst, J. B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Prokop, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, U. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dreier, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuhn, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Knabbe, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Berthold, H. K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pilz, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gouni-Berthold, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gummert, J. F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Boergermann, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zittermann, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-221543
DOI:	10.1186/s12937-017-0270-5
Journal or Publication Title:	Nutr. J.
Volume:	16
Date:	2017
Publisher:	BIOMED CENTRAL LTD
Place of Publication:	LONDON
ISSN:	1475-2891
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language D DEFICIENCY; INTRAVENOUS CALCITRIOL; HEMODIALYSIS-PATIENTS; 25-HYDROXYVITAMIN D; ELDERLY-PATIENTS; CARDIAC-SURGERY; IMPROVES ANEMIA; DOUBLE-BLIND; METAANALYSIS; MORTALITY Multiple languages Nutrition & Dietetics Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/22154